Tezepelumab
Tezepelumab 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Chronic Obstructive Pulmonary Disease (COPD)、Cardiovascular Events、MACE。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
15 项
全球在招研究
6 项
已进入 III/IV 期
28 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- AstraZeneca
- Taichung Veterans General Hospital
- National Institute of Allergy and Infectious Diseases (NIAID)
- Medical University of Warsaw
- Hopital Foch
- University of Alberta
- Shanghai Pulmonary Hospital, Shanghai, China
- University of Leeds
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、Brazil、加拿大、Chile、中国、Czechia、丹麦、德国、India、意大利、Malaysia、Mexico
正在招募患者的 Tezepelumab 研究
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
III 期招募中美国Brazil加拿大ChileNCT06883305Prospective, Non-interventional Single-arm Study With Tezepelumab to Investigate the Change in Clinical and Patient-reported Outcomes in Patients With CRSwNP in Real-world (PETRICHOR)
不适用招募中德国NCT07633158Taiwan Severe Asthma Biologic Registry
不适用招募中中国台湾NCT06456450A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
III 期招募中美国ArgentinaBrazil加拿大NCT06023589Efficacy of Tezepelumab in Peanut Oral Immunotherapy
II 期招募中美国NCT07015996A Study to Investigate NPS and Symptoms in Chinese Adult Participants With CRSwNP Initiating Treatment With Tezepelumab
III 期招募中中国NCT07520162Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab
III 期招募中中国NCT07363642ReAl-woRld Evaluation of tEzepelumab for Chronic rhinoSinusitis With Nasal Polyps in Russia
不适用招募中RussiaNCT07399665Tezspire Cardiac Events PASS
不适用招募中美国丹麦法国德国NCT06951867Expression of TSLP Isoforms in Asthma
不适用招募中PolandNCT07786870Efficacy of an Anti-TSLP Monoclonal Antibody in the Management of Chronic Bronchial Disease Induced by Bronchiolitis Obliterans Syndrome in Allogeneic Hematopoietic Stem Cells Transplantation Recipients
II 期招募中法国NCT07771855Tezepelumab in the Treatment of Emergency Room Asthma in Adults (TERAA)
IV 期招募中加拿大NCT06705764T2AIR: Real-World Efficacy and Safety of Biologics Targeting Type 2 Inflammation in Asthma and COPD
不适用招募中中国NCT07823842A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
III 期招募中美国Argentina澳大利亚比利时NCT06878261Physical Activity Promotion and Clinical Remission in Severe Asthma
不适用招募中英国NCT07735494
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。